PROTOKOLwiki
COMPOUNDS / SARM / CARDARINE
SARM

CARDARINE

HIGH RISK
BEST FOR:Endurance●●●●○○○○○○4/10
CARDARINE · GW501516 · GW-501516 · GW1516 · GW-1516 · ENDUROBOL · PPAR-Δ AGONIST GW501516
PPAR-δMetabolic ModulatorEnduranceFat LossWADA BannedResearch Chemical

PPAR-δ agonist that shifts fuel use from glucose to lipids, enhancing endurance and fat oxidation; development halted over cancer concerns.

ROUTE / DOSAGE
LOW5mg
STANDARD10-20mg
HIGH30mg+
Note: Typically taken once daily; do not exceed 8 weeks continuous use
CYCLE
6-8 weeks on 4-6 weeks off WADA-prohibited at all times
BIOAVAILABILITY
Good oral bioavailability estimated >50%
ACTIVE DURATION
~24h (subjective)
STORAGE
Room temperature dry away from light store in sealed container
HALF-LIFE
16-24 hours (plasma)
DURATION BREAKDOWN
Total24h+
Onset1-2h
Come up1-3 days (metabolic adaptation required)
Peak2-4h (plasma); 2-4 weeks (ergogenic)
Offset24-48h (plasma); 2-4 weeks (ergogenic fade)
After effects1-2 weeks residual metabolic shift
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Increased fatty acid oxidation
Enhanced endurance capacity
Improved lipid profile
Reduced glucose utilisation
Increased mitochondrial biogenesis
Anti-inflammatory macrophage modulation
§ 02 — RISKS
Rapid multi-organ cancer development in long-term rodent studies — primary reason for clinical development cessation
Severe rhabdomyolysis and hepatotoxicity reported in combination with ostarine (CPK >86000, AST >2500)
Hepatic cytolysis with markedly elevated transaminases documented in clinical case
Potential hormonal disruption including gynecomastia and hypogonadism when consumed in contaminated supplements
No human long-term safety data at any dose
WADA-prohibited at all times — detection possible in hair for months after cessation
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

GW501516 reached Phase II clinical trials for dyslipidemia and metabolic disorders but development was discontinued after long-term rodent studies demonstrated rapid development of multiple cancers across multiple organ systems. Animal models showed improved lipid profiles, insulin sensitivity, and exercise endurance. A published case report documented severe rhabdomyolysis and hepatotoxicity (ALT 922, AST 2558, CPK 86435) in a user combining cardarine with ostarine. WADA has prohibited GW501516 at all times since 2009 under metabolic modulators. No human efficacy or long-term safety data exist at performance-enhancing doses; all risk-benefit assumptions are extrapolated from preclinical studies.

§ 06 — SOURCES
[1]
PubMed PMID 32298044
pubmed.ncbi.nlm.nih.gov ↗
[2]
PubMed PMID 38794285
pubmed.ncbi.nlm.nih.gov ↗
[3]
PubMed PMID 32360434
pubmed.ncbi.nlm.nih.gov ↗
[4]
PubMed PMID 39145153
pubmed.ncbi.nlm.nih.gov ↗
[5]
PubMed PMID 40006519
pubmed.ncbi.nlm.nih.gov ↗
[6]
PubMed PMID 16625823
pubmed.ncbi.nlm.nih.gov ↗
[7]
PubMed PMID 34678947
pubmed.ncbi.nlm.nih.gov ↗
[8]
PubMed PMID 40551438
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT